Skip to main content

Articles

Abemaciclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, achieved an objective response in 1 of 5 heavily pretreated patients with metastatic hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer. Read More ›

Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression. Read More ›

The Evolving Role of Oncology Pharmacists
The Oncology Pharmacist (TOP) spoke with Steve Stricker, PharmD, MS, BCOP at the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference about the importance of provider status, why clinical oncologists may be overlooked by their peers, and the most fulfilling part of his work. Read More ›
An Interview with Steve Stricker, PharmD, MS, BCOP

Left- vs Right-Sided Colon Cancers
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy. Read More ›

During each patient’s laboratory work-up, oncology specialists rely on findings related to the tumor’s estrogen receptor (ER) and progesterone receptor status, as well as the amplification and overexpression of the human epidermal growth factor receptor 2 (HER2), to direct treatment planning.2,3

Read More ›

Treatment of Advanced Breast Cancer: A Clinical Pharmacy Perspective

Depending on the patient’s needs, the clinical pharmacist may also work with other staff members, such as financial counselors or social workers, to optimize patient care. Similarly, clinical pharmacists confer with specialty pharmacists to ensure that insurance issues are resolved so that the patient receives timely access to treatment.

Read More ›

The Importance of Patient Education: A Nurse’s Perspective

It is exciting to see that patients with advanced breast cancer are able to receive additional treatment options, because a primary concern of patients with stage IV breast cancer is a lack of awareness of laboratory and clinical research targeted for those battling advanced disease.

Read More ›

Increasing Focus on Value Related to Cancer Drugs: A Payer Perspective

Outside of initial clinical trials, few tools are available to assess the real-world impact of breast cancer on patients. In a research letter published in February 2017 in the Journal of the American Medical Association, the authors compared the impact of several new cancer drugs on progression-free survival (PFS) with their impact on the patient’s quality of life and annual cost.3

Read More ›

A Look at SIRT Y-90 and the SARAH Trial

Project Aims to Prevent Future Infusion-Related Reactions
An infusion-related reaction documentation tool and grading system and its integration into the electronic health record (EHR) is expected to better identify patients at risk for future reactions, and improve communication among oncology team members. Read More ›

Page 112 of 288